Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Maximum Tolerated Dose”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01117623
What this trial is testing

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Who this might be right for
Neoplasm
Bayer 86
Very early researchStudy completedNCT02042222
What this trial is testing

Novel Dose Escalation to Predict Treatment With Hydroxyurea

Who this might be right for
Sickle Cell Disease
Baylor College of Medicine 70
Early research (Phase 1)Study completedNCT00824135
What this trial is testing

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

Who this might be right for
Hematologic Malignancies
St. Jude Children's Research Hospital 34
Early research (Phase 1)Study completedNCT02751918
What this trial is testing

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Who this might be right for
Ovarian Neoplasms
Bayer 65
Early research (Phase 1)Study completedNCT00124189
What this trial is testing

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Who this might be right for
Chronic Lymphoproliferative Diseases
Geron Corporation 48
Early research (Phase 1)Looking for participantsNCT07061626
What this trial is testing

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

Who this might be right for
EpendymomaHigh Grade Gliomas
Cerenome 56
Early research (Phase 1)Ended earlyNCT02003573
What this trial is testing

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Who this might be right for
Leukemia, Myeloid, Acute
Boehringer Ingelheim 13
Early research (Phase 1)Ended earlyNCT00664586
What this trial is testing

Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

Who this might be right for
Refractory Solid TumorsLymphoma
Erimos Pharmaceuticals 21
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Early research (Phase 1)Looking for participantsNCT07238075
What this trial is testing

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Who this might be right for
Advanced MalignancyAdvanced Solid CancersMetastatic Solid Tumors
Adcytherix SAS 290
Early research (Phase 1)Temporarily pausedNCT07353229
What this trial is testing

68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

Who this might be right for
High Risk MeningiomaRecurrent Meningioma
Thomas Jefferson University 24
Early research (Phase 1)Study completedNCT02745743
What this trial is testing

Phase I Trial of BAY1251152 for Advanced Blood Cancers

Who this might be right for
Hematologic Neoplasms
Bayer 21
Early research (Phase 1)Active Not RecruitingNCT05034497
What this trial is testing

Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Who this might be right for
Leptomeningeal Metastasis
Cerenome 18
Early research (Phase 1)Ended earlyNCT01359618
What this trial is testing

Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

Who this might be right for
Healthy Male
AstraZeneca 16
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)Ended earlyNCT03190967
What this trial is testing

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Who this might be right for
Breast CancerBrain MetastasisBrain Cancer
National Cancer Institute (NCI) 12
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Study completedNCT01893320
What this trial is testing

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 66
Testing effectiveness (Phase 2)Ended earlyNCT03645395
What this trial is testing

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

Who this might be right for
Non-hodgkin Lymphoma
Molecular Templates, Inc. 9
Early research (Phase 1)Study completedNCT00676299
What this trial is testing

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Who this might be right for
Protein Kinase InhibitorsAntineoplastic ProtocolsClinical Trial, Phase 1+4 more
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 19
Next Page